Latacomp Teva Sweden

Timolol maleate and Latanoprost, the active ingredients in Latacomp, are a beta‑blocker and prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latacomp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latacomp, a combination antiglaucoma agent, is indicated for conditions involving elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to prevent optic nerve damage. Ocular hypertension: lowers pressure to reduce the risk of progression to glaucoma. Mixed mechanism glaucoma: provides dual action to control pressure when single‑agent therapy is insufficient.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Redness of the conjunctiva. - Itching or mild allergic reaction. - Dry eye sensation. - Foreign body feeling in the eye.

Serious or Rare Side Effects: - Severe allergic reaction with swelling or pain. - Persistent eye pain or inflammation. - Permanent darkening of the iris. - Worsening of asthma or bronchospasm. - Systemic bradycardia or hypotension. - Unexpected visual loss.

Before using Latacomp, consider the following precautions.

Monitor intra‑ocular pressure: schedule regular eye examinations. Assess respiratory status: avoid in patients with active asthma or severe COPD. Check cardiac function: caution in individuals with bradycardia or heart block. Avoid contact lens wear: lenses may reduce drug absorption. Pregnancy and lactation: use only if clearly needed after risk assessment. Store at room temperature: keep in the original container, protect from light and moisture.

Latacomp may interact with several systemic and ocular agents.

Major Interactions (Avoid): - Non‑selective beta‑blockers (e.g., propranolol): additive systemic beta‑blockade. - Sympathomimetic eye drops (e.g., phenylephrine): may diminish efficacy. - Systemic carbonic anhydrase inhibitors: excessive intra‑ocular pressure reduction.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: potential increase in intra‑ocular pressure. - Other prostaglandin analogs: risk of additive ocular side effects.